Protagonist Therapeutics (PTGX) Enterprise Value (2015 - 2026)

Protagonist Therapeutics has disclosed Enterprise Value across 12 years of filings, most recently posting -$547.8 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$547.8 million, up 4.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$547.8 million (up 4.63% YoY), and the FY2025 annual result was -$567.4 million, down 35.44% from the prior year.
• Enterprise Value came in at -$547.8 million for Q1 2026 at Protagonist Therapeutics, up from -$567.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$230.8 million in Q1 2023 to a low of -$576.1 million in Q3 2025.
• The 5-year median for Enterprise Value is -$341.6 million (2023), against an average of -$407.0 million.
• Across the five-year window, Enterprise Value advanced 27.39% in 2022 and tumbled 79.99% in 2024, its largest moves.
• Protagonist Therapeutics' Enterprise Value stood at -$237.4 million in 2022, then plunged by 43.93% to -$341.6 million in 2023, then declined by 22.63% to -$418.9 million in 2024, then tumbled by 35.44% to -$567.4 million in 2025, then gained by 3.45% to -$547.8 million in 2026.
• The last three Enterprise Value figures came in at -$547.8 million (Q1 2026), -$567.4 million (Q4 2025), and -$576.1 million (Q3 2025), per Business Quant data.